Vivakor, Inc. Announces Ticker Symbol and Registration Statement
IRVINE, Calif.-(Business Wire)-August 31, 2009 - Vivakor, Inc. (OTCBB: VIVK), a biomedical/biotechnology innovation company, announced today that it has been issued the ticker symbol “VIVK” from FINRA and has commenced trading on the Over The Counter Bulletin Board market.
The Company also announced that its Registration Statement for 15 million shares of common stock, filed on form S-1 on August 12, 2009, is now effective. With the S-1 now effective, and once all shares in the S-1 sold, Vivakor will have approximately 65 million shares issued and outstanding, of which 20 million are registered and available to trade on the OTCBB market.
“With our entry into the public capital markets and the S-1 filing now effective, Vivakor has greater access to capital needed to continue the progress of our operations,” said Vivakor Chairman, Matt Nicosia. He added, “We have made great strides in development of several projects, from our Biological Handling division’s patent pending cryo-vials, and the Electro-Optics division’s breakthrough VivaSighttm technology, to our Formulary division’s success of its VIVABlend™ nutraceutical. This step into the public market is the next, natural step in the progression of our strategic plan.”
About Vivakor, Inc.
Vivakor™ is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. The R&D Core at Vivakor (the idea hub) innovates, develops and validates biomedical devices and biotechnologies. Commercialization of Vivakor technologies is accomplished through partnerships with manufacturers and niche-industry marketing and distribution leaders. Vivakor generates revenues through the licensing or sale of its technologies. Vivakor is preparing a portfolio of IP and subsidiaries. These will focus on the commercialization of technologies developed by Vivakor. More information can be found about Vivakor at www.vivakor.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor’s research and development and strategic activities. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The success of such activities depends on a number of factors, including the risks that Vivakor may not generate sufficient cash from operations and from external financing to continue as a going concern or to complete its products under development; that Vivakor may not be successful in securing any licensing, partnering or M&A arrangements; that patents may not issue from its patent applications; that competitors may challenge or design around Vivakor’s patents or develop competing technologies. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
